DISCOUNT-OPTIONSSCHEIN - AMGEN | Real-time BOERSE MUENCHEN 09:46:02 2024-05-23 am EDT | ||
| 1.1 EUR | -9.09% |
|
| Current month | +290.32% | ||
| 1 month | +332.14% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 1.1 | -9.09% |
| 24-05-22 | 1.21 | -15.97% |
| 24-05-21 | 1.44 | +8.27% |
| 24-05-20 | 1.33 | +1.53% |
| 24-05-17 | 1.31 | -6.43% |
Real-time BOERSE MUENCHEN
Last update May 23, 2024 at 09:46 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HC8K4E |
| ISIN | DE000HC8K4E9 |
| Date issued | 2023-08-10 |
| Strike | 300 $ |
| Maturity | 2024-06-19 (27 Days) |
| Parity | 10 : 1 |
| Emission price | 0.6 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.59 € |
|---|---|
| Lowest since issue | 0.2 € |
| Spread | 0.01 € |
| Spread % | 0.88% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
309.4
USD
Average target price
316.1
USD
Spread / Average Target
+2.15%
- Stock Market
- Certificates
- Certificat
